Non-small cell lung cancer+5
RecruitingStudy of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher
Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher
- Disease:Non-small cell lung cancerNon-small cell lung cancer stage III+4
- Substances:Cemiplimab
Spain- Participants:18–64 years · 65+ years
- Substances:Cemiplimab
- Sponsor:ETOP IBCSG Partners Foundation














